Instructions for Gynoflor E (lactobacillus acidophilus, estriol) vaginal tablets
English Product Name
Gynoflor® E
Release Form
Vaginal tablets
Description Gynoflor E
Vaginal tablets are oval, biconvex, white to light beige, with intersperses.
1 tab
lactobacteria acidophilic (lyophilizate) at least 1×108 COE
estriol 0.03 mg
Accessories: lactose monohydrate, microcrystalline cellulose, magnesium stearate, sodium carboxymethyl starch (type A), sodium hydrophosphate.
6 pcs. - end-of-line mesh packages (1) - cardboard packs.
ATX codes Gynoflor E
G02CX Other drugs for use in gynecology
Clinical and pharmacological groups / Group affiliation
Drug regulating the balance of vaginal microflora, with an estrogen component
Active ingredient
- estriol
- lactobacteria acidophilic (lyophilizate)
Pharmacotherapeutic group
Estrogen+eubiotic
Retention conditions Gynoflor E
The drug should be kept out of reach of children at temperatures ranging from 2° to 8° C. Do not freeze.
Expiration date
Shelf life is 3 years. Do not use after expiration date.
Pharmacological effect Gynoflor E
Active ingredients contained in the drug Ginoflor® E, namely estriol and acidophilic lactobacteria, participate in the natural mechanism of maintaining the normal microflora of the vagina.\n\nAcidophilic lactobacteria are one of the main microorganisms in the healthy vagina of a woman, having antagonistic activity against pathogenic and opportunistic microorganisms.\n\nEstriol, a female sex hormone and a short-acting estrogen, contributes to the protective trophic effect on the epithelium of the vagina without systemic effects on the woman's body. Vaginal proliferating epithelium accumulates the glycogen necessary for lactobacilli to function, which produce lactic acid while maintaining the vaginal acidic environment (pH 3.8 to 4.5), which creates adverse conditions for pathogens to develop. Lactobacilli also produce hydrogen peroxide and bacteriocins, which inhibit the growth of pathogens.\n\nVarious factors, such as the use of antibacterial drugs topically or systemically, vaginal infections, systemic disorders, and poor hygiene, can cause vaginal flora to change and lactobacilli to decrease. Use of Ginoflor® E vaginally improves vaginal epithelium condition and restores its normal flora. Lactosis in the vaginal pill as a filler can also be fermented by lactobacilli into lactic acid.\n\n
In postmenopause, hormonal disorders can make the vaginal epithelium thinner and more susceptible to injury. Ginoflora® E helps reduce local symptoms (itching, burning, dryness, and soreness during sexual intercourse) and normalizes epithelial conditions in the vagina and urethra, reducing the likelihood of dystrophic inflammatory processes.\n\nin vitro studies show that acidophilic lactobacteria can reduce pH within hours. Estriol, when used continuously for 6 to 12 days, provides proliferative trophic effects on the vaginal epithelium.
Testimony Gynoflor E
Restoration of normal vaginal balance after local and/or systemic use of antibiotics or other antimicrobial drugs (including bacterial vaginosis, nonspecific vulvovaginitis, and urogenital and sexually transmitted infections in vaginal infections)
treatment of postmenopausal estrogen-dependent atrophic vaginitis, including combined with hormone replacement therapy (GGT).
Method of use, course and dosage Gynoflor E
To achieve the desired effect, vaginal pills are given deep into the vagina at bedtime, preferably in a supine position with the legs slightly flexed.
To restore the vaginal flora normally after antibiotics or other antimicrobial drugs (such as bacterial vaginosis, nonspecific vulvovaginitis, urogenital infections, and sexually transmitted sex diseases) are used, 1 to 2 vaginal tablets should be taken daily for 6 to 12 days.
For postmenopausal estrogen-dependent atrophic vaginitis, 1 vaginal pill taken daily for 6 to 12 days is recommended, followed by a maintenance dose of 1 vaginal pill 1 to 2 times a week.
- Nosology (ICD codes)
- N76
- Other inflammatory diseases of vagina and vulva
- N89.8
- Other noninflammatory diseases of vagina
- N95.2
- Postmenopausal atrophic vaginitis